Trial Profile
Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Petosemtamab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Sponsors Merus
- 01 Mar 2024 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 01 Mar 2024 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 28 Feb 2024 According to a Merus media release, the company plans to provide updated efficacy, durability and safety data of HNSCC cohort in the second half of 2024.